Heidelberg Pharma Participates in Franco-German Joint Venture Emergence Therapeutics and Signs Collaboration and License Agreement
- Heidelberg Pharma contributing Antibody Targeted Amanitin Conjugate technology for Emergence Therapeutics antibody target
- Joint research into development candidates planned
Ladenburg, Germany, 20 November 2019 - Heidelberg Pharma AG (FSE: WL6) today announced that its subsidiary, Heidelberg Pharma Research GmbH, will participate in joint venture Emergence Therapeutics AG together with French and German investors, led by lead investor Kurma Partners. Heidelberg Pharma is involved in the start-up phase both as a partner and via convertible bonds and can gradually increase its stake to around 20% during the seed round.
As a co-partner, Heidelberg Pharma will contribute its proprietary toxin linker technology for Antibody Targeted Amanitin Conjugates (ATACs) as part of a license and development agreement. Heidelberg Pharma will also manufacture the experimental ATAC molecules and contribute to research activities. Emergence Therapeutics will provide antibodies to the partnership.
The partners will work together to manufacture novel ATACs and select a candidate for further development. The initial intention is to develop this candidate up to the preclinical stage, where its efficacy and tolerability can be meaningfully assessed. After this, the plan is to achieve at least clinical proof of concept and test the efficacy and tolerability of the candidate in patients based on follow-on financing.
The license agreement is designed to license the project to a pharma or biotechnology company for further development and marketing after proof of concept. In this case the license agreement provides for regulatory and commercial milestone payments and royalties. As a shareholder, Heidelberg Pharma will also participate in the potential increase in value of the joint venture.
About Heidelberg Pharma
Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company's proprietary therapeutic ATACs as well as in third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma.
Former clinical assets MESUPRON(R) and REDECTANE(R) were partnered for further development and commercialization. Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at www.heidelberg-pharma.com.
About Kurma Partners
Founded in 2009, Kurma Partners is a key European player with offices in Paris and Munich in the financing of innovation in healthcare and biotechnology, from pre-creation to growth capital, notably through Kurma Biofund I through III and Kurma Diagnostics, as well as via strategic partnerships with prestigious European research and medical institutions. The new fund Kurma Biofund III invests in private companies, addressing high unmet medical and patient needs with a portfolio of approximately twelve to fifteen companies, 40% of which being early stage financings and company creations like Emergence Therapeutics. More information is available at www.kurmapartners.com.
This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.